Factors Associated with Increased Mortality in Ceftazidime-Avibactam Recipients
The most critical factors associated with increased mortality in patients receiving ceftazidime-avibactam are higher disease severity scores (APACHE II and SOFA), presence of septic shock, mechanical ventilation requirement, and delayed initiation of therapy beyond 72 hours from index culture collection.
Disease Severity Markers
The strongest predictors of mortality are objective measures of acute illness severity:
- APACHE II score: Each point increase independently predicts mortality at both 14 days (adjusted OR 1.20) and 30 days (adjusted OR 1.27) 123
- SOFA score: Higher scores at admission independently predict both 14-day clinical failure and mortality 134
- INCREMENT score ≥8: Strongly associated with 28-day mortality 4
These scoring systems capture the physiologic derangement that fundamentally drives outcomes, regardless of antimicrobial choice.
Critical Illness Complications
Septic shock emerges as a particularly lethal complication, with adjusted odds ratios ranging from 3.30 at 14 days to 5.74 at 30 days 2. This reflects the profound hemodynamic instability that antimicrobials alone cannot reverse.
Mechanical ventilation requirement at infection onset independently predicts mortality (OR 2.38) 52. This marker identifies patients with severe respiratory compromise who face substantially higher risk regardless of microbiologic cure.
Continuous renal replacement therapy requirement also independently predicts death 3, reflecting multi-organ dysfunction that extends beyond the infection itself.
Timing of Therapy
Delayed initiation of ceftazidime-avibactam is critically important: Starting therapy more than 72 hours after index culture collection substantially increases mortality compared to initiation within 48-72 hours 1. Among patients with SOFA scores >6, early initiation within 4 days is a protective factor against 28-day mortality 4. This time-dependent effect underscores that even optimal antimicrobials lose effectiveness when bacterial burden and inflammatory cascade progress unchecked.
Infection-Specific Factors
Bloodstream infection (bacteremia) independently predicts 14-day mortality (adjusted OR 4.76) 2. The systemic dissemination represents higher bacterial burden and greater inflammatory response.
Carbapenem-resistant organisms (CRO) are associated with increased 14-day mortality (OR 5.93) 2, though this may reflect both organism virulence and delayed appropriate therapy.
Interestingly, Klebsiella pneumoniae specifically showed association with 30-day mortality (OR 15.19, though with wide confidence intervals requiring cautious interpretation) 2.
Patient Characteristics
Older age consistently predicts mortality 4, reflecting diminished physiologic reserve and comorbidity burden.
Malignancy independently predicts both 28-day mortality overall and specifically in patients with SOFA scores >6 4. The immunocompromised state and underlying disease burden compound infection-related mortality.
Charlson comorbidity index predicts 14-day clinical failure 4, capturing the cumulative effect of chronic diseases on treatment response.
Neutropenia independently increases mortality risk (HR 2.28) 6, and multiple studies document that neutropenic patients face substantially higher mortality rates 7.
Chronic kidney disease independently predicts mortality (HR 2.23) 6.
Laboratory Parameters
Elevated C-reactive protein at presentation independently predicts mortality 3, reflecting the magnitude of inflammatory response.
Elevated procalcitonin levels associate with higher mortality 1, serving as another marker of severe bacterial infection and systemic inflammation.
Conversely, rising serum albumin during treatment accompanies lower 30-day mortality (OR 0.89) 2, potentially reflecting improving nutritional status and resolving inflammation.
Factors NOT Associated with Mortality
Importantly, combination therapy versus monotherapy shows no mortality benefit in multiple studies 88888. The guidelines note that indication bias toward more severely ill patients likely explains the lack of effectiveness of combination therapy 88. This finding is consistent across observational studies and meta-analyses for CRE infections.
Prolonged infusion (3 hours) of ceftazidime-avibactam and appropriate renal adjustment were associated with 30-day survival in one large Italian study 9, supporting optimal dosing strategies.
Clinical Implications
The evidence reveals that mortality in ceftazidime-avibactam recipients is primarily driven by the severity of underlying illness and timing of appropriate therapy, not by treatment regimen choices (monotherapy vs. combination). The critical window for intervention is narrow—therapy must begin within 72 hours of culture collection, and preferably within 48 hours for critically ill patients.
Common pitfall: Assuming combination therapy improves outcomes in severely ill patients. The evidence shows no benefit, and the apparent association in some studies reflects confounding by indication—sicker patients receive combinations, not that combinations help sicker patients 88.
Key actionable factors: Prioritize patients requiring mechanical ventilation, those with septic shock, and those with high APACHE II/SOFA scores for aggressive supportive care. Ensure ceftazidime-avibactam initiation within 48-72 hours of positive cultures. Monotherapy is sufficient—avoid unnecessary combination therapy and its associated toxicity.